Format

Send to

Choose Destination
J Cancer Res Clin Oncol. 2017 Apr;143(4):613-617. doi: 10.1007/s00432-016-2322-1. Epub 2016 Dec 18.

Distribution of TERT promoter mutations in primary and metastatic melanomas in Austrian patients.

Author information

1
Department of General Dermatology, Medical University Graz, Graz, Austria.
2
Translational Skin Cancer Research - TSCR, DKTK Partner Site Essen/Düsseldorf, German Cancer Research Consortium, University of Duisburg Essen, Universitätsstrasse 1, Essen, 45141, Germany.
3
Division of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg, Germany.
4
Department of Dermatology, University Hospital of Essen, Essen, Germany.
5
Department of Dermatology, University Hospital of Würzburg, Würzburg, Germany.
6
Department of General Dermatology, Medical University Graz, Graz, Austria. j.becker@dkfz.de.
7
Translational Skin Cancer Research - TSCR, DKTK Partner Site Essen/Düsseldorf, German Cancer Research Consortium, University of Duisburg Essen, Universitätsstrasse 1, Essen, 45141, Germany. j.becker@dkfz.de.
8
Department of Dermatology, University Hospital of Essen, Essen, Germany. j.becker@dkfz.de.

Abstract

BACKGROUND:

TERT promoter mutations were detected at high frequencies in several cancer types including melanoma. Previous reports showed that these recurrent mutations increase TERT gene expression and the use of TERT mutation status as prognostic factor was suggested.

OBJECTIVES:

Here we screen a panel of 115 melanoma tumor samples from Austrian patients to evaluate the prevalence and distribution of TERT promoter mutations. The association with clinical and tumor characteristics and the effect on overall survival was analyzed.

METHODS:

Genomic DNA from formalin-fixed paraffin-embedded tumor samples was isolated followed by PCR amplification, Sanger sequencing and statistical analysis.

RESULTS:

We identified TERT promoter mutations in 63 of 115 (54.8%) tumor samples. No statistical significant difference in mutation frequency between primary (22/40 [55%]) and metastatic lesions (41/75 [54.7%]) was detected. BRAF-/NRAS-mutated tumors showed a higher frequency of TERT mutations (pT OR 2.24, 95% CI 0.56-9.02, p = 0.3) (met OR 2.74, 95% CI 0.98-7.66, p = 0.05). In primary melanoma, the presence of alterations in TERT was associated with the carrier status of a common single-nucleotide polymorphism rs2853669 (OR 4.55, CI 1.18-17.52, p = 0.03). In this patient cohort, TERT promoter mutations were not associated with clinical characteristics such as the presence of ulceration or Breslow thickness or showed an effect on overall survival.

CONCLUSION:

Alterations in the TERT promoter region are one of the most frequent mutations in melanoma. Based on this analysis and preliminary evidence, prospective studies will be needed to evaluate the reliability of TERT promoter mutations as prognostic factors in melanoma.

KEYWORDS:

Melanoma; Metastatic lesion; Primary tumor; TERT promotor mutation

PMID:
27990595
DOI:
10.1007/s00432-016-2322-1
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center